![](/images/graphics-bg.png)
Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain
المؤلفون المشاركون
Skljarevski, Vladimir
Dueñas Tentori, Héctor J.
Frakes, Elijah P.
Heinloth, Alexandra N.
Sagman, Doron
Lipsius, Sarah
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-12، 12ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-08-29
دولة النشر
مصر
عدد الصفحات
12
التخصصات الرئيسية
الملخص EN
We summarize efficacy and safety findings from 4 double-blind, placebo-controlled, 12-week studies and 1 open-label, uncontrolled, 34-week maintenance-of-effect (MOE) study that examine duloxetine 40 and 60 mg once daily (QD) in patients with diabetic peripheral neuropathic pain (DPNP).
In all placebo-controlled studies, duloxetine showed significantly (P≤.01) greater reduction in pain severity (weekly mean of 24-hour average pain severity ratings, primary outcome measure) compared with placebo.
In all placebo-controlled studies, duloxetine showed significantly (P≤.05) greater improvement on brief pain inventory-Interference ratings.
Patient global impression of improvement ratings were superior to placebo (P≤.01) for duloxetine patients in all placebo-controlled studies.
Response rates (based on 30% pain reduction) ranged from 57% to 68% for duloxetine and from 35% to 47% for placebo and were statistically significantly different (P≤.01) between treatment groups in 3 out of 4 studies.
The open-label study showed maintenance of analgesic effect of duloxetine in DPNP.
In the duloxetine groups, 4.3% to 14.9% of patients discontinued because of adverse events (placebo groups: 2.6% to 7.4%).
Most commonly reported treatment-emergent adverse events were nausea, somnolence, and headache.
Duloxetine 40 and 60 mg QD was efficacious and well tolerated in the management of DPNP.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Skljarevski, Vladimir& Frakes, Elijah P.& Sagman, Doron& Lipsius, Sarah& Heinloth, Alexandra N.& Dueñas Tentori, Héctor J.. 2012. Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain. Pain Research and Treatment،Vol. 2012, no. 2012, pp.1-12.
https://search.emarefa.net/detail/BIM-506465
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Skljarevski, Vladimir…[et al.]. Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain. Pain Research and Treatment No. 2012 (2012), pp.1-12.
https://search.emarefa.net/detail/BIM-506465
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Skljarevski, Vladimir& Frakes, Elijah P.& Sagman, Doron& Lipsius, Sarah& Heinloth, Alexandra N.& Dueñas Tentori, Héctor J.. Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain. Pain Research and Treatment. 2012. Vol. 2012, no. 2012, pp.1-12.
https://search.emarefa.net/detail/BIM-506465
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-506465
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)